LONDON – LawFuel – Law News + Business – Allen & Overy LLP has advised Takeda Pharmaceutical Company Limited on the acquisition of Paradigm Therapeutics Limited. Paradigm, which has been renamed Takeda Cambridge Limited, has become a subsidiary of Takeda Europe Holdings B.V., a wholly owned subsidiary of Takeda.
Paradigm was founded in 1999, and has established world-class target identification and validation capabilities based on genetic engineering and in vivo pharmacology. Paradigm has already developed a promising pipeline of novel drug discovery targets and compounds in key areas of unmet medical need including pain, CNS disorders, prostate and breast cancer, diabetes, hyperlipidemia, and obesity.
The acquisition will add another research base in each of the UK and Singapore to Takeda’s existing research functions in Japan and the US.
The Allen & Overy team was led by Corporate partner Anna Buscall, assisted by Emma Barnett. IP partner Colleen Keck assisted by Nigel Parker advised on commercial and intellectual property matters, and Kenneth Oh assisted by Yi Jing Teo advised in Singapore.
Commenting Anna Buscall said: “This acquisition is an important strategic step for Takeda, in their goal to become a truly world class pharmaceutical company. We were very pleased to work closely with the Takeda team on their first M&A transaction in Europe. ”
